Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-Operative ICI and Cryoablation in Early Stage TNBC
NCT03546686Phase 2Active, not recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Nov 2019
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, ipilimumab and nivolumab in triple negative breast cancer (TNBC), sponsored by UT Southwestern Medical Center. Primary endpoint: Event-Free Survival at 36 Months. Started Nov 2019; status: active, not recruiting.
02
Drugs
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03546686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546686.